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Abstract
Background: The effectiveness of inhaled aerosolized antibiotics is limited by poor ventilation of infected
airways. Pulmonary delivery of antibiotics emulsified within liquid perfluorocarbon [antibacterial per-
fluorocarbon ventilation (APV)] may solve this problem through better airway penetration and improved spatial
uniformity. However, little work has been done to explore emulsion formulation and the corresponding effects
on drug delivery during APV. This study investigated the effects of emulsion formulation on emulsion stability
and the pharmacokinetics of antibiotic delivery via APV.
Methods: Gravity-driven phase separation was examined in vitro by measuring emulsion tobramycin con-
centrations at varying heights within a column of emulsion over 4 hours for varying values of fluorosurfactant
concentration (Cfs¼ 5–48mg/mL H2O). Serum and pulmonary tobramycin concentrations in rats were then
evaluated following pulmonary tobramycin delivery via aerosol or APV utilizing sufficiently stable emulsions of
varying aqueous volume percentage (Vaq¼ 1%–5%), aqueous tobramycin concentration (Ct¼ 20–100mg/mL),
and Cfs (15 and 48mg/mL H2O).
Results: In vitro assessment showed sufficient spatial and temporal uniformity of tobramycin dispersion
within emulsion for Cfs ‡15mg/mL H2O, while lower Cfs values showed insufficient emulsification even
immediately following preparation. APV with stable emulsion formulations resulted in 5–22 times greater
pulmonary tobramycin concentrations at 4 hours post-delivery relative to aerosolized delivery. Concentra-
tions increased with emulsion formulations utilizing increased Vaq (with decreased Ct) and, to a lesser extent,
increased Cfs.
Conclusions: The emulsion stability necessary for effective delivery is retained at Cfs values as low as 15mg/mL
H2O. Additionally, the pulmonary retention of antibiotic delivered via APV is significantly greater than that of
aerosolized delivery and can be most effectively increased by increasing Vaq and decreasing Ct. APV has been
further proven as an effective means of pulmonary drug delivery with the potential to significantly improve
antibiotic therapy for lung disease patients.
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Introduction
Chronic bacterial respiratory infections are theprimary cause of morbidity and mortality in patients
with cystic fibrosis (CF),(1,2) as well as the main cause of
exacerbation in chronic obstructive pulmonary disease
(COPD).(3,4) Conditions such as CF and COPD feature
changes in mucus rheology and mucociliary clearance that
can make bacterial elimination exceedingly difficult.(5,6)
Antibacterial perfluorocarbon ventilation (APV) has been
previously presented as a possible means of pulmonary an-
tibiotic delivery in which the lungs are filled with aqueous
antibiotics emulsified in perfluorocarbon (PFC) (i.e., water-
in-PFC).(7)
During APV, the lungs are either partially filled with emul-
sion and ventilated with gas (i.e., partial APV) or fully filled
and ventilated with emulsion (i.e., total APV). APV is pro-
posed as a short-term (£ 2 hours) adjunct therapy to systemic
or inhaled antibiotics that could wash infected mucus from
the lungs while delivering antibiotic to poorly ventilated
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regions. Mucus removal during ventilation with PFCs has
been previously noted(8,9) and occurs due to both buoyant
forces and flow-induced shear stress acting on the mucus.
The water-in-PFC emulsions used during APV consist of
small droplets of aqueous antibiotic (diameter previously
shown to be 1–4lm)(7) suspended within a continuous PFC
phase (‡ 95% by volume). Due to the immiscibility of water
and PFC, a small amount of fluorosurfactant is used to
stabilize the droplets and delay their coalescence and
creaming by lowering the aqueous–PFC interfacial tension.
Initial studies of APV have shown its ability to achieve
increased pulmonary retention of delivered antibiotics while
producing lower and delayed peak serum concentrations
relative to aerosolized delivery.(7) This presents the potential
for not only increased efficacy in eradicating infection but
also the opportunity for the administration of larger antibi-
otic doses without increased risk of systemic toxicity.
APV should also result in more spatially uniform drug
delivery throughout the lung relative to aerosolized delivery.
The effectiveness of aerosolized antibiotic delivery is limited
by its inherent dependence on airflow within the lung. Poor
ventilation during disease due to lung damage or mucus
plugging can result in significantly decreased aerosolized
delivery to the most burdened regions of the lung.(10–12)
Furthermore, the significant effects of aerosolized particle
size on site of deposition often results in substantial deposi-
tion in the oropharynx and delivery device, typically resulting
in 25–90% of delivered drug never reaching the lung.(13)
Delivery is further impaired for patients on a mechanical
ventilator in which approximately 20% or less of the de-
livered drug reaches the lung with the majority deposited in
the delivery device and ventilator tubing.(14,15) PFC, on the
other hand, has shown uniform spatial distribution in the
injured lung during liquid ventilation.(16) Additionally, the
physical characteristics that determine this distribution
(viscosity and surface tension) are retained, and possibly
enhanced, following the emulsification process.(7)
During total APV, the lungs are completely filled with
emulsion and thus the airway surfaces throughout the entire
lung are in constant contact with the emulsion. During
partial APV, the lung is filled to a lesser degree, typically to
end-expiratory volume. In this setting, the entire lung would
experience contact with the emulsion at the end of each
expiration while some of the larger conducting airways
would be gas filled during the rest of the respiratory cycle.
Ultimately, by filling the lungs with a liquid and removing
dependence on airflow, APV should result in more efficient
delivery and spatially uniform drug distribution within the
lung relative to currently used treatments.
Optimization of APV requires an understanding of the
temporal patterns of drug delivery and removal from the lung.
However, the pharmacokinetics of these emulsions are
complicated and not yet fully understood. We hypothesize
that the pharmacokinetics during APV are a function of the
aqueous volume percentage (Vaq), aqueous antibiotic con-
centration (Ct), and fluorosurfactant concentration (Cfs). The
Vaq and Ct are defined as the percentage of aqueous phase in
the emulsion and the antibiotic concentration within that
aqueous phase, respectively. Together they define the total
amount of drug delivered to the lungs upon initiating APV.
The fluorosurfactant is responsible for maintaining emul-
sion stability and avoiding droplet coalescence and creaming.
Cfs, therefore, is likely to affect the transport of antibiotic to the
lung parenchyma and pulmonary capillaries. Throughout this
work, Cfs values are specified as a ratio of fluorosurfactant
mass to aqueous volume (i.e., mg per mL H2O). Previous
studies indicate that in vitro bacterial killing of Pseudomonas
aeruginosa biofilms is optimized by maximizing Ct with a far
smaller increase in killing with increasing Vaq.
7 However, the
in vivo setting is a vastly different scenario with a more
complex geometry and multiple transport processes continu-
ally affecting antibiotic presence and availability.
Therefore, this study sought to determine the effect of
Vaq, Ct, and Cfs on antibiotic delivery to the lung. Because
the fluorosurfactant enables the emulsification of the anti-
biotics within the PFC phase, there is a minimum Cfs value
below which the dispersion of drug is not maintained fol-
lowing sonication and the potential for improved pulmonary
distribution is lost. In order to establish an appropriate range
of Cfs values to be examined in vivo, an additional in vitro
study was performed to determine the minimum value of Cfs
that exhibited sufficiently stable drug dispersion.
Materials and Methods
Tobramycin–PFC emulsion preparation
Tobramycin–PFC emulsions were prepared similar to
methods described elsewhere using the same combination of
fluorosurfactants.(7) Briefly, Krytox 157 FSL (DuPont,
Wilmington, DE, USA) and Krytox-PEG copolymer (syn-
thesized as previously described)(17) were first dissolved in
PFC liquid. The PFC used in all experiments was per-
fluorocycloether/perfluorooctane (FC-770; 3M Inc., St. Paul,
MN, USA), although a PFC with a larger amount of docu-
mented in vivo safety would likely be used for eventual
clinical translation. Next, tobramycin (X-Gen Pharmaceu-
ticals Inc, Horseheads, NY, USA) dissolved in sterile water
was added to the PFC solution. The mixture was then
emulsified via sonication (Model S-450D, 3.2mm diameter
microtip; Branson Ultrasonics, Danbury, CT, USA) at 200
W/cm2 for 60 seconds. If the emulsion was not used imme-
diately following preparation, it was sonicated a final time at
the same settings immediately prior to experimentation.
In vitro assessment of emulsion drug dispersion
The spatial distribution of tobramycin-containing aqueous
droplets within a column of emulsion was evaluated over a
period of 4 h following emulsion preparation in order to
evaluate the effect of Cfs on emulsion stability. Emulsions
with fixed Vaq (2.5%) and Ct (40mg/mL) were examined
with varying Cfs (5, 15, or 48mg/mL H2O). A graduated
cylinder (polystyrene, 12.7mm inner diameter) was filled
with 30mL of freshly sonicated emulsion to a height of
approximately 24 cm. The graduated cylinder was modified
to feature access ports with a needle (18 gauge) protruding
through the cylinder wall into the center of the column lu-
men at heights of 4, 10, and 16 cm from the base. A sche-
matic of the graduated cylinder can be seen in Figure 1.
At 0, 30, 120, and 240min following emulsion preparation,
a 200lL sample of emulsion was drawn from each height. In
order to quantify the presence of active tobramycin in each
sample of emulsion, the samples were diluted with 4mL of
sterile water and re-sonicated at 200W/cm2 for 2min,
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resulting in an inverted emulsion (continuous aqueous phase
with dispersed PFC phase). The phase inversion was visually
confirmed by the observation of PFC droplets accumulating
at the bottom of the continuous aqueous phase. The inverted
emulsion was then centrifuged at 3000 g for 20min in order to
separate the PFC and aqueous phase.
The presence of active tobramycin in the separated aque-
ous phase was then quantified via a microbiological assay
similar to that described elsewhere.(18) Briefly, the surface of
LB agar plates was inoculated with 500lL of mid-log growth
Pseudomonas aeruginosa in tryptic soy broth. Aqueous
samples were then diluted and loaded into wells (75lL/well)
within the inoculated agar along with standard solutions of
known tobramycin concentration. The plates were then in-
cubated at 37o C for 24 hours before circular inhibition zones
were imaged and measured. The concentration of the un-
known samples was then determined by interpolation from
the inhibition zones of the standard solutions.
Each sample was measured in triplicate and the resulting
values averaged to produce a single concentration. The
lower limit of detection using these methods was 5 lg/mL,
although all experimental values were well above this limit.
Three separate trials were performed for each emulsion
formulation. All emulsion formulations evaluated had a total
emulsion tobramycin concentration of 1mg/mL. In theory,
if the tobramycin were homogenously distributed through-
out the emulsion and all tobramycin was recovered during
the emulsion inversion process, the assayed aqueous phase
would have a tobramycin concentration of 50lg/mL. Ex-
perimental values from this study were normalized by this
value and are thus reported as a percentage of the theoretical
tobramycin content.
Pharmacokinetic evaluation
Pulmonary delivery of tobramycin (15mg/kg) was
achieved in specific pathogen-free, male Sprague Dawley
rats [n= 40, weight 416 – 16 g (mean – standard deviation);
Taconic, Hudson, NY, USA] via either intratracheal aero-
solized delivery or partial APV with various emulsion for-
mulations. All rats were initially anesthetized with a mixture
of ketamine hydrochloride [50mg/kg, intraperitoneal (IP);
Hospira Inc., Lake Forest, IL, USA] and xylazine hydro-
chloride (5mg/kg, IP; Lloyd Laboratories, Shenandoah, IA,
USA).
Following initial anesthesia, intravenous (IV) access was
acquired via the lateral tail vein, and a constant IV infusion of
ketamine hydrochloride (1mg/kg/min) was used to maintain
sedation for the remainder of the experiment. Heart rate and
arterial oxygen saturation were monitored via a pulse oxi-
meter (VetOx Plus 4800; Heska, Loveland, CO, USA). Rat
body temperature was monitored and maintained with a ho-
meothermic blanket system (Model 507220F; Harvard Ap-
paratus, Holliston, MA, USA). Rats receiving aerosolized
treatment were then orally intubated with a 16 gauge angio-
catheter and placed in a supine position. Aerosolized delivery
was accomplished via a Microsprayer Aerosolizer (Model
IA-1B; Penn-Century, Wyndmoor, PA, USA).
Prior to intubation, the length of the angiocatheter was
trimmed to ensure that the Microsprayer nozzle was suffi-
ciently exposed when the Microsprayer was fully inserted
into the angiocatheter. Following intubation with the trim-
med angiocatheter, the Microsprayer was fully inserted into
the angiocatheter and tobramycin (40mg/mL tobramycin
concentration, 15mg/kg bodyweight) was delivered in-
tratracheally. Although efforts were made to synchronize
actuation of the Microsprayer to inspiration, the rats often
became temporarily apneic following intubation and thus
the aerosol was sometimes delivered in the absence of in-
spiratory or expiratory flow.
Following delivery, rats were extubated and provided
supplemental oxygen via a nose cone until euthanasia. For
rats receiving partial APV, the neck was shaved and cleaned
with alcohol and a 1 cm midline incision made. The trachea
was isolated and a tie positioned loosely around it. The rat
was then orally intubated with a 16 gauge angiocatheter and
connected to a ventilator (Model 683; Harvard Apparatus)
in a supine position. Immediately after beginning ventilation
the tie was tightened around the trachea, creating a seal on
the angiocatheter already within the trachea.
Ventilation was carried out with a tidal volume of 9mL/kg
bodyweight, a respiratory rate of 50–80 breaths/min, a
positive end-expiratory pressure of 3 cmH2O, and a fraction
of inspired oxygen of 1. Respiratory rate was adjusted to
maintain peak inspiratory pressures less than 30 cmH2O.
Preoxygenated emulsion was instilled (15mL/kg body-
weight) via a port connected to the angiocatheter, resulting
in a delivered dose of 15mg/kg bodyweight of tobramycin.
The emulsion was prepared no more than 5min before use
and was instilled during gas ventilation in successive ali-
quots (2–3mL/aliquot) with each aliquot instilled over a
period of approximately 60 s. Gas ventilation was continued
following delivery of the emulsion until euthanasia.
The delivery methods and emulsion formulations used are
summarized in Table 1. In order to evaluate the isolated effect
FIG. 1. A schematic of the graduated cylinder used during
in vitro assessment of emulsion drug dispersion. Access
ports to the cylinder lumen are featured at heights of 4, 10,
and 16 cm from the base.
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ofVaq andCt, emulsionswith constantCfs (15mg/mLH2O)and
varying Vaq (1%, 2.5%, and 5%) were assessed. Ct was varied
inversely with Vaq in order to maintain a constant delivered
dose of tobramycin. Similarly, in order to evaluate the effect of
Cfs, emulsionswith constantVaq (2.5%) andCt (40mg/mL) and
varying Cfs (15 or 48mg/mL H2O) were assessed.
Additionally, tobramycin delivery via a combination of
PFC and aqueous tobramycin without fluorosurfactant was
evaluated using a modified partial APV procedure. Due to the
immiscibility of the two phases in the absence of fluor-
osurfactant, the emulsion delivery procedure previously de-
scribed was slightly modified in order to achieve accurate and
consistent delivery. For this group, neat PFC was instilled in
an identical fashion to that described for emulsion delivery
during partial APV. Next, the angiocatheter was temporarily
disconnected from the ventilator and the aqueous tobramycin
phase intratracheally delivered via the Microsprayer. As with
the aerosolized delivery group, the angiocatheters used in this
treatment were appropriately trimmed in order to ensure
uninhibited aerosol delivery. The rats were then reconnected
to the ventilator and the remainder of the experiment carried
out as described above.
In all experiments, blood samples were drawn via the
lateral tail vein (opposite side of the tail relative to IV in-
fusion) at 30, 60, 120, and 240min following delivery of
tobramycin. In treatment groups showing peak serum con-
centrations 30min post-delivery, treatment was repeated
with blood samples drawn at 10, 20, and 30min post-
delivery in order to better determine the time and magnitude
of peak serum concentrations. A hematocrit measurement
was taken at the time of each blood sampling and was used
to normalize serum tobramycin measurements to account for
hemodilution due to IV fluid delivery. Five rats were ana-
lyzed for each set of conditions evaluated.
Rats were euthanized with pentobarbital sodium (175mg/kg,
IP, Fatal Plus; Vortech Pharmaceuticals, Dearborn, MI,
USA), the trachea immediately tied off with suture, and the
lungs and trachea removed intact. The lungs were then thor-
oughly homogenized with sterile saline (25mL/kg body-
weight). After centrifugation, supernatant from homogenized
lung tissue samples was collected, serially diluted, and the
presence of active tobramycin measured via the previ-
ously described microbiological assay. Any result below the
lower limit of detection (5 lg/mL) was assigned a value of
2.5 lg/mL. Serum tobramycin concentration measurements
were performed via an immunoassay by the Laboratory
Medicine Department within Allegheny General Hospital
(Pittsburgh, PA).
Statistical analysis
SPSS 22 (IBM Corporation, Armonk, NY) was used to
perform all statistical analysis. A one-way ANOVA and
post-hoc analysis was performed on the peak serum to-
bramycin concentrations and lung tissue tobramycin con-
centrations. Due to unequal variances between groups, the
Games-Howell method was used to determine significant
differences. A mixed model analysis was performed to ex-
amine differences in the serum tobramycin concentrations
with time post-delivery used as the repeated-measure vari-
able. A similar analysis was also used in the in vitro stability
studies to examine differences in tobramycin content, using
time post-preparation and height as the repeated-measure
variables.
Results
In vitro assessment of emulsion drug dispersion
The formation of a distinct aqueous layer of varying sizes
was observed at the top of the emulsion column between 0
and 30 minutes post-preparation for all trials performed.
Figure 2 shows tobramycin content for emulsions (Vaq= 2.5%
and Ct= 40mg/mL) with Cfs values of 5, 15, and 48mg/mL
H2O. In Figure 2A, tobramycin content is shown as a function
of height for each Cfs value and time point examined. Figure
2B shows the same data as a function of time for each Cfs
value and height examined. Results showed a significant
( p< 0.01) effect of Cfs on tobramycin content.
Tobramycin content resulting from a Cfs of 5mg/mL H2O
was significantly ( p<0.01) lower than that for Cfs values of
both 15 and 48mg/mL H2O. Emulsion utilizing a Cfs value of
5mg/mLH2O showed insufficient dispersion of antibiotic, even
immediately following preparation and was thus not evaluated
during the in vivo pharmacokinetic experiments. Tobramycin
content for Cfs of 15 and 48mg/mL H2O did not significantly
differ from each other. No significant effect was shown for time
post-preparation or height on tobramycin content.
Pharmacokinetic evaluation
Lung tissue homogenate tobramycin concentrations at 4
hours post-delivery for all treatments evaluated are shown in
Figure 3. Two of the five aerosolized delivery trials and all
five of the aerosolized delivery in combination with PFC
Table 1. Delivery Methods and Corresponding Formulations of All Treatments Evaluated
Delivery
method [-]
Aqueous
volume
percent, Vaq [%]
Aqueous
tobramycin
concentration,
Ct [mg/mL]
Emulsion
tobramycin
concentration
[mg/mL emulsion]
Ratio of
each Krytox
and Krytox-PEG
mass to aqueous
volume, Cfs
[mg/mL H2O]
Total
concentration
of each Krytox
and Krytox-PEG
[mg/mL emulsion]
APV 1.0 100 1 15 0.15
APV 2.5 40 1 15 0.375
APV 5.0 20 1 15 0.75
APV 2.5 40 1 48 1.2
Aerosol + PFC 2.5 40 N/A 0 0
Aerosol 100.0 40 N/A N/A N/A
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trials resulted in concentrations below the lower limit of
detection (5 lg/mL). All APV treatments resulted in sig-
nificantly (either p< 0.01 or p < 0.05, see Fig. 3 for dis-
tinction) greater pulmonary tobramycin concentrations
relative to aerosolized delivery at 4 hours post-delivery. As
shown in Figure 3A, pulmonary tobramycin concentrations
increased with increasing Vaq (decreasing Ct), with the
largest Vaq (5%) resulting in 22 times greater concentration
than aerosolized delivery. As shown in Figure 3B, increased
Cfs also resulted in larger pulmonary tobramycin concen-
trations, although the difference between the two Cfs values
examined was not significant ( p = 0.14).
Serum tobramycin concentrations for all treatments are
shown in Figure 4. A Vaq of 5% resulted in significantly
( p< 0.01) lower serum tobramycin concentrations relative
to all other groups shown in Figure 4A. Similarly, the largest
value of Cfs (48mg/mL H2O) had significantly ( p < 0.01)
lower serum tobramycin concentrations than all other
groups shown in Figure 4B. The time and magnitude of peak
serum concentrations for all treatments evaluated are shown
in Table 2. Peak serum concentrations in all APV groups
occurred at a later time point than both aerosolized delivery
alone and in combination with PFC (60min post-delivery
for APV groups vs. 10min post-delivery for aerosol groups).
FIG. 2. Tobramycin content within the emulsion (normalized by theoretical value) as a
function of height from the base of the column for varying Cfs values and times post-
preparation (A) and as a function of time post-preparation for varying Cfs values and
heights from the base of the column (B). Error bars represent standard deviations and n = 3
for each condition evaluated.
FIG. 3. (A) Tobramycin concentration of lung tissue homogenate at 4 hours following
tobramycin delivery via aerosolized delivery and partial APV with varying values of Vaq.
(B) Tobramycin concentration of lung tissue homogenate at 4 hours following tobramycin
delivery via aerosolized delivery, aerosolized delivery in combination with PFC, and
partial APV with varying Cfs values. Error bars represent standard deviations, n = 5 for
each condition evaluated, and statistically significant differences between groups are de-
noted by an asterisk (*p< 0.05, **p < 0.01).
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Peak serum concentrations resulting from aerosolized de-
livery or aerosolized delivery in combination with PFC were
greater than all those produced by APV, although not sig-
nificantly different in all cases.
At the same Cfs value (15mg/mL H2O), a Vaq of 5%
produced significantly ( p< 0.01) lower peak serum concen-
trations than the 1% and 2.5% Vaq groups and aerosolized
delivery. Similarly, a Cfs of 48mg/mL H2O produced sig-
nificantly ( p< 0.01) lower peak serum concentrations relative
to a Cfs of 15mg/mL H2O, aerosolized delivery, and aero-
solized delivery in combination with PFC.
Discussion
In order to achieve effective antibiotic therapy, the anti-
microbial agent must reach the site of infection and remain
in the vicinity for an adequate length of time.(19) In the case
of pulmonary treatment in the setting of lung disease, de-
livery to the site of infection is challenging. Inhaled aero-
solized treatment is currently the most widely used and
successful means of achieving such delivery. However, lung
disease can result in poor ventilation in many of the airways,
rendering a delivery method relying on airflow less than
ideal. APV provides a means of pulmonary drug delivery
with no dependence on airflow and thus increased ability to
achieve effective delivery throughout the lung.
Previous work has proven APV to be a viable means of
pulmonary antibiotic delivery, as well as shown the bacte-
ricidal ability of emulsions against CF-derived Pseudomo-
nas aeruginosa biofilms.(7) However, the effects of emulsion
formulation on the resulting antibiotic delivery have yet to
be fully investigated. Understanding these effects is a vital
step in optimizing the emulsion formulation for safe and
effective treatment. In this study we sought to evaluate the
effects of emulsion formulation (Vaq, Ct and Cfs) on emul-
sion stability as well as the pharmacokinetics of antibiotic
delivery via APV.
As the long-term biocompatibility of the fluorosurfactants
used (or rather any available fluorosurfactants) has not been
evaluated, there is warranted caution regarding their use in the
lung. This only highlights the importance of understanding the
effects of the amount of fluorosurfactant used in order to de-
termine the degree to which it can be minimized without im-
pairing effective drug delivery. Results from this work suggest
that a Cfs value as low as 15mg/mL H2O (a nearly 70% re-
duction from previous APV in vivo trials)(7) still exhibits
uniform drug dispersion up to 4 hours following preparation.
As noted in previous work with APV, the emulsion
preparation is straightforward and could be performed im-
mediately prior to administration, similar to processes for
drug-laden emulsions used in chemoembolization.(20) Thus,
FIG. 4. (A) Serum tobramycin concentration out to 240min following tobramycin de-
livery via aerosolized delivery and partial APV with Cfs = 15mg/mL H2O and varying Vaq
values. (B) Serum tobramycin concentration out to 240min following tobramycin delivery
via aerosolized delivery, aerosolized delivery in combination with PFC, and partial APV
with Vaq= 2.5% and varying Cfs values. Error bars represent standard deviations, and n = 5
for each condition evaluated.
Table 2. Peak Serum Concentrations After Tobramycin Delivery
Delivery
method [-]
Aqueous
volume
percent, Vaq [%]
Ratio of
each Krytox
and Krytox-
PEG mass to
aqueous volume,
Cfs [mg/mL H2O]
Time to
peak serum
concentration
[min]
Peak
serum
concentration
[mg/mL]
APV 1.0 15 60 8.7 – 0.9
APV 2.5 15 60 9.4 – 1.2
APV 5.0 15 60 4.7 – 1.6
APV 2.5 48 60 2.3 – 0.7
Aerosol + PFC 2.5 0 10 16.1 – 3.9
Aerosol 100.0 N/A 10 10.8 – 2.7
Concentration values are reported as mean – standard deviation.
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even the reduced value of Cfs (15mg/mL H2O) evaluated
should be able to maintain uniform drug dispersion for the
entirety of the intended treatment duration (£2 hours). This
reduction of Cfs also caused a slight decrease in pulmonary
antibiotic retention, but the effect of this retention on the
anti-biofilm activity of the emulsion is not yet known.
The presence of antibiotics within the lung following
treatment was evaluated by measuring the tobramycin con-
centration of homogenized lung tissue via a microbiological
assay. A significant advantage of this detection method is the
assurance that the measured tobramycin content is still active
and able to exert its intended bactericidal effect. The most
clinically relevant measure of antibiotic presence in the lung
is likely the aqueous concentration at the airway surfaces,
however, such a measurement is difficult to perform in rats.
Due to the complex environment present within the air-
ways during APV, it is difficult to speculate how the to-
bramycin concentrations of lung tissue homogenate relate to
the concentrations encountered at the aqueous surfaces of
the lung. A greater understanding of the physical transfer of
drug from the emulsion to the aqueous surfaces which it
encounters would likely best be accomplished in a more
controlled in vitro setting and should be a primary aim of
future efforts towards advancing APV.
When interpreting the pharmacokinetic results of this
work, it is also important to note that emulsion was not
suctioned from the lungs prior to euthanasia and subsequent
tissue tobramycin measurements. This differs from the
clinical scenario in which some portion of the emulsion,
along with dislodged mucus and biofilm, would be suctioned
from the lungs within 2 hours of delivery.
From the authors’ previous experience performing APV
in rats, suctioning emulsion from the airways of a rat has
proven to be technically difficult and highly inconsistent.
Thus, during APV treatment in this work, the emulsion was
allowed to remain in the lungs in order to reduce treatment
variability. The volume of emulsion remaining in the lungs
at the time of euthanasia was not measured in this work.
However, a previous study evaluating liquid ventilation with
neat PFC in similarly sized rats has shown an evaporative
loss rate of 1.6mL/hour.(21) The average amount of emul-
sion instilled during this study was 6.2mL. Although the
evaporative loss rate likely decreases with time, one would
expect very little, if any, emulsion to remain in the lungs
after 4 hours of ventilation at the time of euthanasia and
tissue tobramycin measurement.
Similar to a previous study,(7) increased pulmonary anti-
biotic concentrations were measured following APV (all
emulsion formulations) relative to aerosolized delivery.
Aerosolized delivery in combination with PFC showed low
retention similar to aerosolized delivery alone. During such
delivery, the aerosol droplets likely initially deposited on the
epithelium or PFC surface. Any further dispersion of the
aqueous drug would have relied solely on the mixing in-
duced by tidal gas flow once ventilation was resumed. These
results suggest that the increased retention of delivered drug
observed during APV is likely a result of the initial dispersion
of the aqueous drug throughout the PFC and the presence of
fluorosurfactant. Although ventilation with PFC has been
shown to alter the distribution of pulmonary perfusion,(22) the
similar lack of retention between aerosolized delivery alone
and in the presence of PFC would suggest that PFC-induced
differences in pulmonary blood flow are likely not the pri-
mary cause of the retention associated with APV.
Regarding effects of emulsion formulation, increasing either
Vaq or Cfs was shown to increase pulmonary retention, al-
though the effect of Vaq was much stronger. A five-fold in-
crease in Vaq (and corresponding five-fold decrease in Ct)
resulted in a nearly identical increase in pulmonary tobramycin
content 4 hours post-delivery. In the case of Cfs, an approxi-
mately three-fold increase resulted in a less than 50% increase
in pulmonary retention. These results indicate that increased
Vaq in combination with decreased Ct slows diffusion of to-
bramycin from the airways into the pulmonary circulation.
Antibiotics are believed to move between the bronchial
space and blood at a rate dependent on the concentration
gradient between the two compartments.(23) During APV, as
aqueous droplets come in to contact and combine with the
aqueous lining of the airways, the local antibiotic concen-
tration near the epithelium increases thus increasing diffu-
sion into the blood. The rate at which this occurs is
determined by both the frequency of droplet deposition as
well as the antibiotic concentration within each droplet (i.e.,
Ct). An increase in Vaq increases the number of droplets and
as such could increase the frequency of droplet deposition.
However, these results suggest that increased Vaq does not
increase droplet deposition enough to compensate for the
decreased antibiotic mass within each droplet, leading to an
overall slowed diffusion for increased Vaq and decreased Ct.
Although not as profound as with Vaq, increases in Cfs
also showed increased pulmonary antibiotic retention at 4
hours post-delivery. Additionally, serum tobramycin con-
centrations resulting from the largest Cfs value (48mg/mL
H2O) were significantly lower than those at 15mg/mL H2O,
further suggesting delayed antibiotic absorption into the
pulmonary circulation for increased Cfs. The cause of this
diminished absorption at increased values of Cfs is not yet
fully understood.
In vitro assessment of emulsion stability showed no dif-
ference between Cfs values of 15 and 48mg/mL H2O (both
emulsions exhibited uniform antibiotic distribution) and
thus suggests that the observed pharmacokinetic effect of
Cfs is likely not due to gravity-driven phase separation.
However, it is possible that coalescence and creaming is
altered for emulsion in the airways at physiological tem-
peratures under constant ventilation as compared to our
in vitro experiment. Increased phase separation within
emulsion in the airways for the 15mg/mL H2O group could
enhance and accelerate contact between tobramycin within
the bulk of the emulsion and epithelial surfaces through
which it may ultimately leave the lungs.
Alternatively, the diminished absorption effects could be
due to the accumulation of fluorosurfactant at the inter-
face between the emulsion and airway aqueous lining. The
fluorosurfactant molecules possess both hydrophilic and
fluorophilic moieties and thus aggregate at aqueous–PFC
interfaces. It is possible that some amount of fluorosurfactant
accumulates at the boundary of the lung aqueous lining and
impairs either the deposition of droplets or the diffusion of
tobramycin following deposition. Further in-depth studies are
needed to fully understand the effects of fluorosurfactant on
drug transport from the emulsion in a physiological setting.
Considering the results of this study, the optimal emul-
sion formulation for APV may utilize a significantly reduced
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Cfs value as compared to previous work (Cfs= 48mg/mL
H2O in previous studies).
(7) Additionally, pulmonary re-
tention of the delivered antibiotic can be most effectively
increased by increasing Vaq and decreasing Ct to achieve the
desired delivery dose. However, it is unknown whether the
rate of tobramycin delivery from the airway to the tissue has
a significant effect on anti-biofilm activity and thus treat-
ment efficacy. Studies comparing rapid, nearly complete
delivery of the antibiotic must be compared to slower,
controlled delivery. Whatever the outcome, the ability to
reliably control such kinetics represents an attractive quality
of pulmonary drug delivery via PFC emulsions.
There are multiple factors to consider when choosing an
optimal Vaq and Ct for treatment. As Ct is decreased, a
scenario could be approached in which the aqueous con-
centration of antibiotics in the lung during APV is less than
that required for bacterial killing. A previous study with
APV has shown that emulsions utilizing Ct values as low as
4mg/mL (five-fold smaller than lowest Ct value used in
present study) were still able to reduce proliferation of
biofilm-derived bacteria following exposure.(7)
Additionally, as Vaq is increased, larger aqueous volumes
will be delivered to the lung during APV. Therefore caution
should be used when determining Vaq as to not increase this
value to the point of inhibiting normal respiratory function. If
the Vaq values evaluated in this study (1%–5%) were to be
used clinically during partial APV with a 15mL/kg dose of
emulsion (dose used in previous clinical trials of partial liquid
ventilation), a 70-kg patient would receive approximately
10–50mL of aqueous antibiotic delivered to the lung. How-
ever, at the conclusion of treatment, some portion of the
emulsion would be suctioned from the lung. Conservatively,
estimating that only one-third of the emulsion volume would
be removed from the lung, 7–35mL of aqueous antibiotic
would ultimately remain in the lung. During currently used
nebulized tobramycin treatment for CF patients, approxima-
tely 10mL of aqueous antibiotics are delivered to the lung on
a daily basis.(24) Considering that such treatment is generally
well tolerated without supplemental oxygen or ventilatory
support, the range of Vaq values used in this work are likely
within reason for a patient on mechanical ventilation.
The current study has confirmed the use of APV as a viable
and effective means of pulmonary antibiotic delivery and
taken critical steps in further developing this emerging
technology. APV utilizing an optimized emulsion formula-
tion should result in increased pulmonary retention, de-
creased and delayed peak serum concentrations, as well as
improved dispersion of delivered antibiotic relative to aero-
solized delivery. Future studies should evaluate the efficacy
of an optimized emulsion during APV in an animal model of
lower respiratory infection, as well as the biocompatibility of
the used fluorosurfactants and any others available.
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